Bionure project of the GAEM’s Accelerator Programme raises more than €1M via equity crowdfunding Blog Post

With more than €1M raised, Bionure’s campaign ‘#estamosaesto‘ (‘we are this close’) is currently overfunding on the Capital Cell crowdfunding platform.These funds will be used by the company to develop BN201, a promising first-in-class drug candidate halt the development of Multiple Sclerosis (MS). Bionure’s MS drug candidate is one of the projects promotes by the Accelerator Programme of GAEM Foundation from its headquarters at the Barcelona Science Park (PCB).

 

Minoryx successfully completes phase 1 clinical trial for lead candidate MIN-102 Blog Post

Minoryx Therapeutics – a drug development company specialized in the discovery and development of new drugs for orphan diseases, which has R& D laboratories at the Barcelona Science Park– announces that it has successfully completed its phase 1 trial with its lead compound MIN-102 targeting X-linked adrenoleukodystrophy (X-ALD), a life threatening orphan CNS disease with high unmet medical need.

 

Samuel receives the Catalonian National Research Award for Young Talent Blog Post

Yesterday IBEC group leader and ICREA research professor Samuel Sánchez at PCB, received the Catalonian National Research Award for Young Talent from the Catalan Government and the Catalan Foundation for Research and Innovation (FCRI).This prestigious honour and cash prize of €10,000 aims to encourage and acknowledge young researchers whose work and research has stood out during their professional career.

 

The AECC supports cancer research at IRB Barcelona Blog Post

Today, Jelena Urosevic and Carles Barceló, postdoctoral fellows at the Institute for Research in Biomedicine (IRB Barcelona) at the Barcelona Science Park, will officially be presented with funding over 5 years from the Asociación Española Contra el Cáncer (AECC) for their respective research projects on colon cancer. To date, IRB Barcelona has secured AECC funding for eight cancer projects.

 

The FBG receives € 150,000 from the AECC for childhood cancer research Blog Post

The project on neuroblastoma led by Elisa Martí Gorostiza, researcher at the Institute of Molecular Biology of Barcelona (IBMB-CSIC), based at PCB, and the Catalan Biotechnology Reference Network (XRB), has received one of the three grants for research projects on childhood cancer funded by the Spanish Association Against Cancer (AECC). The € 150,000 grant, obtained with the collaboration of the XRB, will be managed by the Bosch i Gimpera Foundation (FBG).

 

The Barcelona Science Park has strong presence at BIO-Europe Spring Blog Post

BIO-Europe Spring (BES) –the spring edition of the most important partnering congress in the biotechnology and pharmaceutical industry in Europe– returns to Barcelona in 20-22 March 2017 at the CCIB Convention Centre. After the success of the 2010 and 2013 editions, more than 100 companies and organizations from the BioRegion will be participating in the fair, twice as many as the previous year. This edition features remarkable presence of the Barcelona Science Park (PCB) and a large number of companies and entities from PCB Community.

 

CataloniaBio grants the ‘BioSuccess of the Year’ award to STAT-Diagnostica Blog Post

The Catalan Association of Biotechnology Companies (CataloniaBio) has recognized Stat-Diagnostica –founded in 2010 at the Barcelona Science Park by Jordi Carrera and Rafael Bru– with the ‘Biosuccess of the Year’ Award. The prize giving ceremony was held yesterday at the Museu Maritimo of Barcelona under his winter networking event CataloniaBio Gala Dinner, a yearly meeting organised by this business association with the aim of enhancing scientific-business cooperation in Catalonia in the field of life sciences and health.

 

New research front to tackle Friedreich’s Ataxia Blog Post

The associations of patients and families Babel Family and the Asociación Granadina de la Ataxia de Friedreich (ASOGAF) channel 80,000 euros of their donations (50% from each organisation) into a new 18-month project at the Institute for Research in Biomedicine (IRB Barcelona) located at PCB. The long-term goal of the project is to achieve an injectable frataxin treatment able to reach the brain. Frataxin is the protein that is reduced in those affected by this rare and degenerative disease, which has no cure.